Mayo Clinic | Strategic Alliance Partners

December 23, 2022

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

December 22, 2022

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.

December 20, 2022

Jeanne M. Palmer, MD, discusses a retrospective analysis of the PERSIST-1 and PAC203 trials, the symptoms that were analyzed across patient populations, and what the findings from this research indicate about the relationship between low platelet counts and symptoms such as fatigue in myelofibrosis.

December 19, 2022

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

December 08, 2022

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

December 06, 2022

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

December 05, 2022

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

December 01, 2022

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

October 31, 2022

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

October 25, 2022

Investigators hope to add RLY-4008, the first highly selective FGFR2 inhibitor, to the growing arsenal of treatment options for patients with cholangiocarcinoma.

October 07, 2022

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

October 03, 2022

Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.

September 27, 2022

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

September 19, 2022

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

September 19, 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

September 10, 2022

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

September 09, 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

September 02, 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

August 29, 2022

Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

August 29, 2022

Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.